A Study to Evaluate ALN-6222 in Participants With Obesity

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity

This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.

Inclusion Criteria -

• Is an adult patient with a body mass index ≥30 kg/m^2 to <40 kg/m^2
• Has a hemoglobin A1c <6.5%

Exclusion Criteria -

• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN)
• Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
• Has an estimated glomerular filtration (eGFR) of <60 mL/min/1.73m^2 at screening

Note: other protocol defined inclusion / exclusion criteria apply